Blue Owl Capital Holdings LP Trims Stock Holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Blue Owl Capital Holdings LP trimmed its holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 16.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 450,339 shares of the company’s stock after selling 90,741 shares during the quarter. Mineralys Therapeutics makes up about 1.5% of Blue Owl Capital Holdings LP’s portfolio, making the stock its 19th biggest position. Blue Owl Capital Holdings LP’s holdings in Mineralys Therapeutics were worth $5,269,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of MLYS. PNC Financial Services Group Inc. raised its holdings in shares of Mineralys Therapeutics by 17,821.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,122 shares of the company’s stock worth $35,000 after buying an additional 4,099 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Mineralys Therapeutics by 67.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,931 shares of the company’s stock worth $102,000 after purchasing an additional 3,181 shares during the period. Bellevue Group AG purchased a new position in Mineralys Therapeutics during the 1st quarter worth $119,000. Federated Hermes Inc. raised its position in Mineralys Therapeutics by 100.0% during the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock valued at $140,000 after purchasing an additional 6,000 shares in the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in Mineralys Therapeutics during the 2nd quarter valued at $145,000. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Jon Congleton sold 15,746 shares of Mineralys Therapeutics stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $13.34, for a total value of $210,051.64. Following the transaction, the chief executive officer now directly owns 911,212 shares in the company, valued at approximately $12,155,568.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Brian Taylor Slingsby sold 550,000 shares of Mineralys Therapeutics stock in a transaction on Wednesday, July 24th. The stock was sold at an average price of $13.05, for a total value of $7,177,500.00. Following the transaction, the director now directly owns 8,644,579 shares in the company, valued at approximately $112,811,755.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jon Congleton sold 15,746 shares of Mineralys Therapeutics stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $13.34, for a total value of $210,051.64. Following the completion of the transaction, the chief executive officer now owns 911,212 shares in the company, valued at $12,155,568.08. The disclosure for this sale can be found here. In the last three months, insiders have sold 577,028 shares of company stock worth $7,536,774. 33.24% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Mineralys Therapeutics in a research report on Thursday, August 15th.

Mineralys Therapeutics Stock Down 0.8 %

Shares of NASDAQ MLYS opened at $11.90 on Friday. The business has a fifty day simple moving average of $11.82 and a two-hundred day simple moving average of $12.41. The firm has a market cap of $590.82 million, a PE ratio of -5.43 and a beta of 1.93. Mineralys Therapeutics, Inc. has a twelve month low of $5.85 and a twelve month high of $16.91.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its earnings results on Tuesday, August 13th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.10). During the same quarter last year, the company earned ($0.31) earnings per share. On average, research analysts expect that Mineralys Therapeutics, Inc. will post -3.08 earnings per share for the current year.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.